EMCDDA publications: archives
Consumptions most impacted by COVID-19
01.2022 - The EMCDDA European Web Survey on Drugs reveals that cannabis and ecstasy use are the most impacted by COVID-19 restrictions.
Health and social responses to drug problems
10.2021 - EMCDDA releases new European miniguides on responding to drug problems.
Methamphetamine from Afghanistan
09.2021 - This EMCDDA report examines the phenomenon and identifies actions to mitigate the risks in Europe.
Hepatitis C in Europe
07.2021 - EMCDDA Elimination barometer and its Manual about hepatitis C.
Drugs and prison in Europe
06.2021 - Current insights and future challenges on drugs and prison in a new EMCDDA study
New benzodiazepines in Europe
06.2021 - EMCDDA technical review of new benzodiazepines monitored by the EU Early Warning System.
ESCAPE Report 2018-2019
02.2021 - EMCDDA multi-city syringe study uncovers latest patterns of injecting drug use.
Emerging methamphetamine industry in Afghanistan
11.2020 - This EMCDDA paper also highlights an expanding market for ephedra.
ESPAD Report 2019
11.2020 - Comprehensive picture of the present addiction situation among 15–16-year-old school students.
Impact of COVID-19 on patterns of drug use and drug-related harms in Europe
06.2020 - The EMCDDA instigated a mixed-method trendspotter study to investigate the current situation.
EU Drug Markets — Impact of COVID-19
05.2020 - Joint publication from the EMCDDA and Europol.
COVID-19 – Drug supply via darknet markets
05.05.2020 - This EMCDDA report is a rapid and preliminary analysis of the impact of COVID-19 on selected online markets.
COVID-19 and people who use drugs
25.03.2020 - Up-to-date information can be found in the guidelines prepared by national public health sources and the regular updates from the European Centre for Disease Prevention and Control (ECDC) and the World Health Organization (WHO).
Monitoring changes in cannabis policies
31.01.2020 - Insights from the Americas about monitoring and evaluating changes in cannabis policies.
New EMCDDA Scientific Committee appointed
17.12.2019 - The EMCDDA Management Board appointed 15 high-level scientists to serve on the agency’s Scientific Committee for the period 2020–22.
Developments in the European cannabis market
25.06.2019 - Cannabis products have become increasingly diverse in Europe. This report explores the issues that it raises.
Laura d’Arrigo reelected as EMCDDA's Chair
14.12.2018 - The EU agency's Management Board held elections for the positions of Chair and Vice-Chair of the Board.
Recent changes in Europe’s cocaine market
13.12.2018 - Using trendspotter methodology, this report explores signs of increasing availability and consumption of cocaine.
Medical use of cannabis
04.12.2018 - EMCDDA's first report on this topic, as more European countries develop policies and practice in this area.
Drug use in recreational settings
15.11.2018 - A new EMCDDA report deals with monitoring drug use in recreational settings and ways to build a picture of this phenomenon.
Today's captagon illicit market
22.10.2018 - A new EMCDDA report draws on and complements Drugs, international challenges No. 10.
Two new opioïds under control across the EU
28.09.2018 - two fentanyl-related substances, cyclopropylfentanyl and methoxyacetylfentanyl, have been placed under control across the EU.
New psychoactive substances in prison
07.06.2018 - Preliminary analysis of a ‘trendspotter’ study carried out by the EMCDDA in 2017.
Drug-related homicide in Europe
25.05.2018 - The EMCDDA releases a paper providing an overview of the information available on drug-related homicide (DRH) in Europe.
Cannabis and driving : briefing for policy making
23.05.2018 - This briefing aims to provide those concerned with policy in this field.
Two cannabinoids under control in the EU
14.05.2018 - the Council of the EU has decided to subject ADB-CHMINACA and CUMYL-4CN-BINACA to control measures.
Wastewater analysis in 56 european towns
07.03.2018 - Findings of the largest European project to date presented today by the Europe-wide SCORE group, in association with the EMCDDA.
EMCDDA-Europol Joint Reports on 2 new opioids
28.02.2018 - See the joint reports published on cyclopropylfentanyl and on methoxyacetylfentanyl in accordance with Article 5 of the EU Council Decision 2005/387/JHA.
Drug supply monitoring
07.12.2017 - The EMCDDA presents in a new paper its current thinking on the conceptual framework for monitoring drug markets, crime and supply reduction.
Drugs and the darknet
28.11.2017 - The EMCDDA and Europol present the latest understanding of how darknet markets function, the threats they pose to health and security and how Europe can respond.
Drug testing in schools
22.11.2017 - This EMCDDA paper (17 p.) evaluates the effectiveness of random testing in schools, based on studies conducted students aged 13 to 19 years, in the United States.
Furanylfentanyl under control across the EU
15.11.2017 - the EU has decided to subject the new synthetic opioid to control measures. Member States will have one year to introduce them into national legislation.
EMCDDA-Europol Joint Report on carfentanyl
13.11.2017 - See the joint report published by the 2 organizations in accordance with Article 5 of the EU Council Decision 2005/387/JHA.
Drugs in Europe
2021 EMCDDA European Drug Report
How is the COVID-19 pandemic affecting drug use, supply and services?
Drug use and harms
What are the health costs of drug use in Europe today?
What do the latest data tell us about drug production and trafficking trends?
These and other questions are explored in the 2021 European Drug Report, our annual overview of the drug situation in Europe.
The annual Statistical Bulletin contains the most recent available data on the drug situation in Europe provided by the Member States. These datasets underpin the analysis presented in the European Drug Report. All data may be viewed interactively on screen and downloaded in Excel format..
The European Union and the drug phenomenon
The European Union & the drug phenomenon : Frequently asked questions, joint publication between the EMCDDA and the European Commission, october 2010, 12 p.